Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alvine Pharmaceuticals has said that the first study subject was dosed in a single-blind, placebo controlled, dose-escalation Phase I clinical trial of its lead clinical candidate ALV003, which is in development for the treatment of patients with celiac disease.
Subscribe to our email newsletter
Approximately 36 subjects are planned for enrollment in the trial to be conducted in the US. Both healthy human volunteers and subjects with celiac disease are expected to be dosed in this trial.